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Apolipoprotein (apo) E, a constituent of several li-
poproteins, is a ligand for the low density lipoprotein
receptor, and this interaction is important for maintain-
ing cholesterol and triglyceride homeostasis. We have
used a gene replacement strategy to generate mice that
express the human apoE3 isoform in place of the mouse
protein. The levels of apoE mRNA in various tissues are
virtually the same in the human apoE3 homozygous (3/3)
mice and their littermates having the wild type mouse
allele (1/1). Total cholesterol and triglyceride levels in
fasted plasma from the 3/3 mice were not different from
those in the 1/1 mice, when maintained on a normal
(low fat) chow diet. We found, however, notable differ-
ences in the distribution of plasma lipoproteins and apo-
lipoprotein E between the two groups: b-migrating li-
poproteins and plasma apoB100 levels are decreased in
the 3/3 mice, and the apoE distribution is shifted from
high density lipoproteins to larger lipoprotein particles.
In addition, the fractional catabolic rate of exogenously
administered remnant particles without apoE was 6-fold
slower in the 3/3 mice compared with the 1/1 mice.
When the 3/3 and 1/1 animals were fed a high fat/high
cholesterol diet, the 3/3 animals responded with a dra-
matic increase (5-fold) in total cholesterol compared
with the 1/1 mice (1.5-fold), and after 12 weeks on this
same diet the 3/3 animals developed significantly (at
least 13-fold) larger atherosclerotic plaques in the aortic
sinus area than the 1/1 animals. Thus the structural
differences between human APOE3 and mouse ApoE
proteins are sufficient to cause an increased susceptibil-
ity to dietary-induced hypercholesterolemia and ather-
osclerosis in the 3/3 mice.
Apolipoprotein (apo)1 E is important for the transport of
cholesterol and triglyceride throughout the body. It is an am-
phipathic protein that stabilizes the structure of lipoprotein
particles via its ability to bind lipid, and it functions as a ligand
for lipoprotein receptors, such as the low density lipoprotein
receptor (LDLR) and the low density lipoprotein receptor-re-
lated protein (1–3). ApoE is a major protein component of
chylomicron remnants, very low density lipoproteins (VLDL),
and intermediate density lipoproteins (IDL), but it is not pres-
ent on low density lipoproteins (LDL). ApoE is also enriched in
a subclass of high density lipoproteins (HDL) and functions as
an effective ligand for their binding to the LDLR (4).
The human APOE gene is located on chromosome 19 (5) as
part of an apolipoprotein cluster that also includes the genes
encoding APOCI, APOCII, and APOCIV (6). Multiple tissue-
specific enhancers and negative elements have been identified
in the region proximal to the gene (7). A distal enhancer, the
hepatic control region, that is required for liver expression is
located 15 kb downstream of the gene (8, 9). The liver synthe-
sizes approximately 70% apoE found in the body and 20% is
found in the brain, and the remainder is synthesized in several
tissues including the spleen, lung, heart, ovary, testis, kidney,
and skin (10, 11).
Three major APOE alleles, e2, e3, and e4, occur in humans at
frequencies of 7.3, 78.3, and 14.3%, respectively (12). These
three alleles are distinguished by coding differences at posi-
tions 112 and 158 (13). The most common isoform, apoE3, has
a cysteine at position 112 and an arginine at position 158; the
apoE2 isoform has a cysteine at both positions, whereas the
apoE4 isoform has an arginine at both positions. Functionally,
the three isoforms differ in their affinity for the LDLR, with
apoE3 and E4 exhibiting 100% binding and apoE2 displaying
only 1% normal binding affinity (14). Despite the lower affinity
of apoE2 for the LDLR, individuals homozygous for e2 typically
have lower than normal plasma cholesterol levels, except for
the fraction of homozygotes (5–10%) who develop type III hy-
perlipoproteinemia (15). Individuals homozygous for e4 have
higher total plasma cholesterol and LDL cholesterol compared
with e3 homozygotes and are at increased risk for developing
coronary artery disease (16). The e4 allele is also associated
with the development of Alzheimer’s disease (17, 18).
ApoE isoform-specific effects are important in the etiology of
atherosclerosis and other diseases, but appropriate animal
models to rigorously investigate these effects are currently
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lacking. To date, transgenic animals made by pronuclear injec-
tion of human DNA have been used to study these effects, but
this method produces mice with varying levels of transgene
expression due to differences in chromosomal location and copy
number, and expression of the endogenous mouse apoE com-
plicates the interpretation of the data (19–24, 47). To overcome
these difficulties we have used targeted gene replacement to
generate mice that express only the human apoE3 isoform at
levels that are in the physiological range. In these mice the
coding sequences for mouse apoE were replaced with sequences
coding for human APOE3 without disturbing any of the known
regulatory sequences. This replacement results in animals
with expression of human apoE mRNA, identical in tissue
distribution and levels, to that of mouse apoE mRNA in wild
type animals.
We here describe the essentially normal cholesterol and trig-
lyceride levels of mice homozygous for human apoE3 (3/3) when
maintained on a normal (low fat) mouse chow diet but show
that they are markedly more susceptible to diet-induced ath-
erosclerosis than their wild type littermates (1/1).
EXPERIMENTAL PROCEDURES
Targeting Construct—The targeting construct was made by inserting
into a pPNT vector (25), a 4.1-kb SacI human genomic fragment iso-
lated from a plasmid, pHEG-1 (20), kindly provided by Dr. John Taylor
at the University of California, San Francisco. This fragment contains
the 39 part of intron 1 (723 base pairs), exons 2–4 of the human APOE3
gene, and 1.5 kb of 39-flanking DNA. A 5.3-kb EcoRI-SacI strain 129
mouse genomic fragment containing sequences upstream of the mouse
apoE gene including exon 1 and the 59 part of intron 1 (376 base pairs)
was inserted 59 to the human APOE3 fragment. A 1.4-kb PvuI-KpnI
strain 129 mouse genomic fragment containing the 39-half of exon 4 and
39-flanking sequence was inserted downstream of the neomycin-resis-
tant gene in pPNT (see Fig. 1, below).
Generation of Homozygous Human apoE3 Mice—A subclone (BK4) of
mouse strain 129 embryonic stem (ES) cell line, E14TG2a, was cultured
and electroporated with the human apoE3 targeting construct as de-
scribed previously (26). Targeted ES cell clones were identified by
Southern blot analysis. Chimeras were generated and mated with
C57BL/6J (B6) mice. F2 generation mice were used for all of the exper-
iments described. Mice were kept on a normal (low fat) chow diet
consisting of 5% (w/w) fat and 0.022% (w/w) cholesterol (Prolab RMH
3000, number 5P76, St. Louis, MO) or on an atherogenic diet that
contains 15.8% (w/w) fat, 1.25% (w/w) cholesterol, and 0.5% (w/w)
sodium cholate (TK 88051, Teklad Premier, Madison, WI).
Plasma Lipid Measurements—All lipid measurements were per-
formed on mice between the age of 8 and 20 weeks. Animals were fasted
overnight (approximately 16 h), anesthetized with Avertin, and 150 ml
of blood was collected from the retro-orbital sinus into tubes containing
8 mM EDTA, 1 mg/ml aprotinin (Boehringer Mannheim), and 1 mg/ml
gentamycin, and stored on ice. Plasma was removed after centrifuga-
tion at 8,000 3 g for 10 min at 4 °C, and total cholesterol and HDL
cholesterol were measured using diagnostic CII kits (Wako, Richmond,
VA) according to the manufacturer’s instructions. Triglyceride levels
were measured using an enzymatic kit (Sigma).
Plasma Lipoprotein Analysis—Within 1 h of blood collection, 1 ml of
plasma was electrophoresed in precast 1% agarose gels (Ciba Corning
Diagnostics Corp., Palo Alto, CA), and neutral lipids were visualized by
Fat Red 7B staining (Sigma). One ml of pooled plasma from 10 mice
(100 ml each) was separated by sequential density ultracentrifugation
into seven fractions ranging in densities from ,1.006 g/ml to .1.21
g/ml, using the procedure described by de Silva et al. (27). Total lipopro-
teins were isolated from plasma at a density ,1.21 g/ml. Lipoprotein
fractions were dialyzed against 10 mM Tris, pH 7.4, 1 mM EDTA, 150
mM NaCl before electrophoresis in a 3–20% denaturing SDS-PAGE gel
(27). Plasma (100 ml) from either individual or pooled samples were
separated by gel filtration chromatography using a Superose 6 HR10/30
column (Pharmacia Biotech Inc.). Immunoblot analysis of FPLC frac-
tions (2 ml) electrophoresed in precast 1% agarose gels was performed
with antibodies described below.
Northern Blot Analysis—Total RNA was extracted from several tis-
sues according to the method of Chomczynski and Sacchi (28) using
RNAzoly B (Tel-test, Friendswood, TX). Total RNA (20 mg) was elec-
trophoresed in a 1% agarose gel after denaturation with a glyoxal/
Me2SO mixture (29). RNA was transferred to a Hybond membrane
(Amersham Corp.) and hybridized overnight at 42 °C in 50% formam-
ide, 5 3 SSC, 1 3 Denhardt’s solution, 100 mg of salmon sperm DNA, 30
mM sodium phosphate, pH 6.5, and 10% dextran sulfate; the probe was
a mouse exon 4 DNA fragment labeled with [32P]dCTP. The blot was
washed in 3 3 SSC, 0.1% SDS for 10 min at 37 °C and then 0.1 3 SSC,
0.1% SDS for 10 min at 65 °C. The blot was exposed to preflashed Kodak
XAR film for 20 h.
ApoE Enzyme-linked Immunosorbent Assay—Human APOE in
mouse plasma was measured with a sandwich-type enzyme-linked im-
munosorbent assay (ELISA) essentially as described (30). A mouse
anti-human apoE monoclonal antibody, E01 (a huE (m)) (30), was used
as the capture antibody and a goat anti-human apoE antibody (a huE
(p)) (Calbiochem) as the detecting antibody. The a huE (p) antibody
cross-reacts with mouse apoE at a low level. The a huE (m) antibody has
been shown to react with human APOE in all classes of lipoprotein
particles (30) and does not cross-react with mouse ApoE. Values were
determined with a standard curve made with pooled human plasma
whose apoE levels were determined against purified recombinant hu-
man apoE3 (number 178475, Calbiochem) and validated against an
international calibrator (Dr. N. Rifai, Childrens Hospital, Boston, MA).
Mouse ApoE was measured in a similar manner using a purified
rabbit anti-mouse apoE antibody (a muE (m)) (10 mg/ml) raised against
a mouse apoE peptide (residues 179–241) for the capture antibody. The
same antibody conjugated to horseradish peroxidase was used for de-
tection with chromagen. The mouse peptide (residues 179–241) was
used as a standard for determining the concentration of mouse ApoE.
Western Blot Analysis—Fasted whole plasma (1 ml) was electrophore-
sed in a 4–20% denaturing SDS-PAGE gel or in a 1% agarose gel,
transferred to an Immobilon P membrane (Millipore Corp., Bedford,
MA), and reacted with all three anti-apoE antibodies described above.
Immunoreactive proteins were visualized with a horseradish peroxi-
dase conjugate using an enhanced chemiluminescence kit (Amersham
Corp.). Western blots for the analysis of apoB were made similarly
using 4% SDS-PAGE and rabbit anti-mouse apoB sera (gift from Dr.
Steven Young, University of California, San Francisco).
Clearance Assay—Four apoE (2/2) mice were injected with 20 mg of
free cholesterol containing 2.5 mCi of 4-14C-labeled cholesterol dispersed
in an egg lecithin/free cholesterol (1:1 molar ratio) mesophase. The
apoE (2/2) b-VLDL fraction was isolated 36 h later by centrifugation at
1.010 g/ml. More than 72% of the tracer was in the cholesterol ester
fraction (31). Three mice in each group (apoE2/2, 3/3, and 1/1) were
injected with the labeled apoE (2/2) b-VLDL. The fractional catabolic
rates and their variances were determined up to 4 h as described
previously (31).
Evaluation of Atherosclerotic Lesions—Female mice that had been
fed a high fat diet for 3 months were sacrificed by Avertin overdose after
a 16-h fast. The thoracic cavity was opened, and the heart and vascular
system were perfused with 4% paraformaldehyde in phosphate-buff-
ered saline, pH 7.4, under physiological pressure. Segments of the
proximal aorta and aortic sinus were embedded, sectioned, and stained
as described previously (32). Morphometric evaluations of lesion size
were made using the NIH image (version 1.41) software.
Statistical Analysis—The significance of differences between means
was tested by using a two-tailed unpaired Student t test or a nonpara-
metric Mann-Whitney U test.
RESULTS
Replacement of the Mouse apoE Gene with the Human
APOE3 Allele—The targeting strategy used to replace the
mouse apoE coding exons 2–4 with the human counterpart is
illustrated in Fig. 1. Homologous recombination between the
targeting construct (Fig. 1B) and the endogenous mouse apoE
locus (Fig. 1A) results in a chimeric gene (Fig. 1C) where all the
mouse coding sequences have been replaced with sequences
coding for human APOE3. This chimeric locus retains all nor-
mal mouse regulatory sequences in addition to the non-coding
mouse exon one. Identification of correctly modified embryonic
stem (ES) cells was by Southern blot analysis with a mouse
exon 1 or exon 4 probe (data not shown); ES cell DNA digested
with EcoRI and hybridized with the mouse exon 1 probe re-
vealed an 8.3-kb endogenous band and a 7.8-kb targeted band
confirming the correct modification of the 59 region; ES cell
DNA digested with HindIII and hybridized with mouse exon 4
probe revealed a 7.5-kb endogenous band and a 15-kb targeted
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band confirming correct modification of the 39 region. The mod-
ified locus was transmitted to the F1 generation from chimeras
that were made from one of the targeted cell lines. All F1
matings produced normal litter sizes with a normal Mendelian
segregation pattern of the modified locus. Genotypes of F2
animals were determined using Southern blot analysis of tail
DNA digested with BamHI (Fig. 2A). The nucleotide sequence
for codon 112 (TGC) and codon 158 (CGC) in a 3/3 mouse was
confirmed using allele-specific PCR (33) on tail DNA.
Human apoE3 Levels in Whole Plasma—To confirm the pres-
ence of human APOE protein in the mice, plasma (1 ml) from
3/3, 3/1, 1/1 mice, and a human (hu) were electrophoresed in
a 4–20% gradient denaturing SDS-PAGE gel. Western blot
analysis with anti-human apoE antisera (a huE (p)), which
slightly cross-reacts with mouse ApoE, showed that human
APOE (34, 200 Da) in 3/3 plasma migrates at the same rate as
apoE in human plasma and slightly slower than the mouse
apoE (32, 600 Da) in 1/1 plasma (Fig. 2B). The absence of
mouse ApoE in the 3/3 plasma was confirmed by Western blot
analysis with an anti-mouse apoE antibody (a mu (m)), which
shows that mouse ApoE is present only in the 1/1 and 3/1
samples and not in the 3/3 plasma. In contrast, the anti-human
apoE monoclonal antibody (a huE (m)), which does not cross-
react with mouse ApoE, shows that human APOE was present
only in 3/3, 3/1, and human plasma and not in the 1/1 plasma
(Fig. 2B). Western blotting of plasma from two 3/3 mice in a
4–20% nonreducing SDS-PAGE gel showed that human
APOE3 homodimer was present at less than 5% monomeric E3
(Fig. 2C).
The concentration of apoE in 3/3 plasma (1.30 6 0.47 mg/dl)
as determined by ELISA was very similar to the levels (1.13 6
0.23 mg/dl) found in 1/1 plasma (see Table I below).
Tissue Distribution of apoE mRNA—Total RNA was ex-
tracted from several tissues including skin (Sk), spleen (Sp),
kidney (Ki), small intestine (Si), stomach (St), heart (He), testis
(Te), muscle (Mu), lung (Lu), liver (Li), submandibular gland
(Su), and brain (Br) from a 3/3 male mouse and a wild type 1/1
male mouse. Northern blot analysis with a mouse exon 4 probe
was used to compare the levels of apoE mRNA in the two types
of animal (Fig. 3). This probe hybridizes equally well to the
human gene and the mouse gene under the conditions used. A
b-actin probe was hybridized to the same blot after removal of
the apoE probe (lower panels in Fig. 3) to assess the amount of
mRNA loaded in each group. In agreement with previous re-
ports (10, 11) apoE mRNA expression was highest in the liver
FIG. 1. Replacement of the mouse apoE gene with the human APOE3 gene. A, genomic organization of the mouse apoE gene containing
exons 1–4 (black boxes). B, the apoE3 targeting construct containing the 59 and 39 arms of mouse homology (black line and boxes) interrupted by
the human apoE3 gene (hatched boxes 29, 39, and 49, labeled huE3). The neomycin-resistant (Neo) and thymidine kinase (TK) genes are for selection
of the targeted ES cells, and pPNT is the plasmid vector. C, the resulting chimeric gene now encoding human apoE3. The mouse exon 4 probe
(Probe) was used to detect the targeted allele. Sizes of diagnostic fragments are shown (dashed lines). Sites are as follows: E, EcoRI; S, SacI; H,
HindIII; P, PvuI; K, KpnI; X, XbaI; B, BamHI.
FIG. 2. Southern and Western blot analysis. A, Southern analysis
with a mouse exon 4 probe to identify F2 mice carrying the targeted
allele. An 11.2-kb hybridizing BamHI fragment indicates the presence
of the human APOE3 allele. A 4.8-kb hybridizing BamHI fragment
indicates the presence of the mouse apoE allele. B, fasted whole plasma
(1 ml) was electrophoresed in a 4–20% denaturing SDS-PAGE gel, and
the proteins were transferred to an Immobilon P membrane and incu-
bated with either an anti-human apoE antisera (a huE (p)) that weakly
cross-reacts with mouse apoE (top panel) or with an anti-mouse apoE
antibody (a muE (m)) (middle panel) or with an anti-human apoE
monoclonal antibody (a huE (m)) (bottom panel) that does not cross-
react with mouse apoE. C, fasted whole plasma (1 ml) was electrophore-
sed in a 4–20% SDS-PAGE gel, and the proteins were transferred to an
Immobilon P membrane and incubated with a huE (p) antiserum in the
presence (1) or absence (2) of b-mercaptoethanol (b-me). The abbrevi-
ations used are: Hu, human sample; 3/3, sample from homozygous
human apoE3 mouse; 3/1, heterozygous sample; 1/1, wild type sample.
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and second in the brain, with lesser amounts in other tissues.
No apoE mRNA was detected in muscle. The expression of
apoE mRNA in the 3/3 and 1/1 animals was essentially indis-
tinguishable in all tissues analyzed, with the exception of small
intestine which had reduced levels of apoE mRNA in the 3/3
animals compared with 1/1 mice. This Northern blot analysis
clearly demonstrates that the modified locus containing human
apoE3 coding sequences and the wild type mouse gene are
expressed at virtually identical levels in all tissues.
Plasma Lipids and Lipoproteins in Mice Fed Normal Chow—
The levels of total cholesterol (TC), triglycerides, and HDL
cholesterol in female mice fed a normal (low fat) chow diet were
determined in plasma obtained after a 16-h fast (Table I).
There was no difference in TC levels between the 3/3 mice (67 6
18 mg/dl, n 5 30) and the 1/1 controls (73 6 20 mg/dl, n 5 30),
in striking contrast to the total cholesterol levels previously
found in apoE-deficient mice on the same diet (541 6 220
mg/dl, 32). The TC levels in males were higher than females
(p 5 0.0001), but again there were no differences between the
3/3 and the 1/1 group. Triglyceride and HDL cholesterol levels
in the 3/3 mice and the 1/1 mice were also very similar
(Table I).
Fasted wild type (1/1) plasma lipoproteins migrate as three
distinct bands designated a (HDL), b (LDL), and pre-b (VLDL)
using agarose gel electrophoresis (Fig. 4A). Plasma from fasted
3/3 mice, on the other hand, showed an increase in the pre-b
band and the absence of b-migrating lipoproteins relative to
the 1/1 samples. These differences were observed in the
plasma of both male and female 3/3 mice. The amount of
a-migrating particles in the 3/3 and 1/1 mice were the same.
These results suggest that the 3/3 mice have slightly increased
amounts of VLDL/IDL remnants and a reduction of LDL
particles.
To determine the amount of apoB100 relative to apoB48,
equal amounts of whole plasma from a 3/3 and a 1/1 female
mouse were separated in a 4% SDS-PAGE gel, blotted, and
reacted with anti-mouse apoB sera (Fig. 4B). A densitometric
scan of the autoradiograph showed that the 3/3 sample had a
B100:B48 ratio of 1:3 compared with a B100:B48 ratio of 1:0.8
in the 1/1 sample. In a separate experiment total lipoproteins
(density ,1.21 g/ml) were isolated from pooled plasma from
five female 3/3 mice and four 1/1 mice and electrophoresed in
a 3–20% SDS-PAGE gel. Coomassie Brilliant Blue staining of
the gel (Fig. 4C) showed that plasma apoB100 levels in the 3/3
mice were greatly reduced compared with the 1/1 mice and
that apoB48 levels were higher in the 3/3 mice compared with
the 1/1 mice.
Different Distribution of Human and Mouse Apolipoprotein
E—Individual plasma samples and pooled (n 5 10) plasma
samples were separated by gel filtration chromatography on a
Superose 6B column for the determination of cholesterol, tri-
glyceride, and apoE distribution. The distribution of cholesterol
TABLE I
Plasma lipid profiles and apoE concentration in mice fed a normal and a high fat diet
Data are means 6 S.D. of fasted mice receiving chow (C) or high fat (HF) diet. Parentheses show the number of mice. TG, triglyceride.
Genotype Diet TC TG HDL-cholesterol Human apoE3 Mouse apoE
mg/dl mg/dl mg/dl mg/dl mg/dl
Females 3/3 C 67 6 18 (30) 35 6 12 (26) 46 6 11 (26) 1.30 6 0.47 (10)
HF 350 6 207 (17)a 29 6 22 (15) 22 6 11 (14) 10.80 6 5.60 (8)a
1/1 C 73 6 20 (30) 43 6 15 (26) 53 6 15 (23) 1.13 6 0.23 (6)
HF 111 6 44 (17)b 21 6 7 (14) 23 6 15 (13) 1.11 6 0.34 (5)
Males 3/3 C 104 6 22 (15)c 39 6 16 (13) 54 6 19 (7)
1/1 C 95 6 16 (15) 41 6 17 (14) 52 6 15 (7)
a p , 0.01 versus 3/3 females on chow.
b p , 0.001 versus 3/3 females on high fat.
c p , 0.001 versus female 3/3.
FIG. 3. Northern blot analysis of total RNA from various tis-
sues. Total RNA (20 mg) was electrophoresed in a 1% gel, blotted, and
then hybridized to a mouse apoE exon 4 probe, as indicated. The same
filter was rehybridized with a b-actin probe. 3 identifies lanes contain-
ing RNA from human apoE3 mice; 1 identifies lanes containing RNA
from wild type mice; Sk, skin; Sp, spleen; Ki, Kidney; Si, small intes-
tine; St, stomach; He, heart; Te, testis; Mu, muscle; Lu, lung; Li, liver;
Su, submandibular gland; Br, brain.
FIG. 4. Analysis of plasma lipoproteins. A, fasted plasma (1 ml)
from males and females maintained on a normal (low fat) chow diet was
electrophoresed in a 1% agarose gel and stained with Fat Red 7B. The
positions of the a-, b-, and pre-b-lipoproteins are indicated. B, Western
analysis of fasted plasma (1 ml) from female mice using a denaturing 4%
SDS-PAGE gel with an anti-apoB antisera. The positions of the
apoB100 and 48 proteins are indicated. Samples are from 3/3, homozy-
gous human apoE3 mice, and from 1/1, wild type mice. C, total lipopro-
teins (density ,1.21 g/ml) pooled from five female 3/3 and four 1/1 mice
were electrophoresed in a 3–20% SDS-PAGE gel and stained with
Coomassie Brilliant Blue. The positions of the apolipoproteins are as
indicated.
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(solid circles in Fig. 5, A and B) was nearly identical for the 3/3
and 1/1 mice except for a small decrease in fractions 21–24 in
the 3/3 group. This decrease in LDL cholesterol agrees with the
agarose gel electrophoresis results described above. Triglycer-
ide distribution was essentially the same for both groups (data
not shown) with the largest percentage of triglyceride present
in fractions 14–16.
Contrary to the identical distribution of lipids, the distribu-
tion of apoE (open circles in Fig. 5, A and B) in the 3/3 and 1/1
mice was markedly different as determined by ELISA with
mouse- and human-specific antibodies. The majority of apoE in
1/1 mice is present in the HDL region (fractions 26–31) with
only a minor amount present in the VLDL (fractions 14–17)
and IDL-LDL regions (fractions 18–25) (Fig. 5B). Western blot
analysis of 1/1 FPLC fractions electrophoresed in an agarose
gel using the a-huE (p) antisera support the results obtained by
ELISA (Fig. 5D). However in the 3/3 mice the majority of apoE
is present in two very distinct peaks where VLDL (fractions
14–17) and IDL species (fractions 18–21) typically elute (Fig.
5A). Western blots of an agarose gel with each FPLC fraction
are in agreement with the apoE3 distribution as determined by
ELISA (Fig. 5C). SDS-PAGE gel electrophoresis of lipoproteins
fractionated by sequential density ultracentrifugation (Fig. 6A)
showed that apoE3 in the 3/3 mice was found predominantly in
the lower density fractions, d , 1.04 g/ml. No major differences
were detectable in the distributions of apolipoproteins AI in the
3/3 and 1/1 samples and the apoC’s after SDS-PAGE of frac-
tions separated by sequential density ultracentrifugation
(Fig. 6A).
The IDL-like peak in 3/3 plasma is particularly noteworthy
since cholesterol and triglyceride in these fractions are very
low. These IDL-like particles, enriched in apoE3, most likely
represent VLDL/chylomicron remnants since agarose gel elec-
trophoresis of FPLC fractions followed by Western blotting
with a huE (p) antisera demonstrated that the majority of
apoE3 was associated with particles migrating at the pre-b-
position, and association of apoE3 with large HDL particles at
the a-position was minimal (Fig. 5C). FPLC analysis of plasma
after immunoprecipitation with an anti-mouse apoB antibody
FIG. 6. Distribution of apolipoproteins in mice fed either a
normal or high fat diet. A, pooled plasma from 10 mice fed normal
chow were fractionated by sequential density ultracentrifugation, and
each fraction was electrophoresed in a denaturing SDS-PAGE 3–20%
gradient gel and stained with Coomassie Brilliant Blue. Density frac-
tions are: 1.006, ,1.006 g/ml; 1.02, 1.006–1.02 g/ml; 1.04, 1.02–1.04
g/ml; 1.06, 1.04–1.06 g/ml; 1.08, 1.06–1.08 g/ml; 1.10, 1.08–1.10 g/ml;
1.21, 1.10–1.21 g/ml. B, the same as above except mice were fed a high
fat diet for 3 months.
FIG. 5. Distribution of cholesterol and apoE in mice fed normal chow. A and B, pooled plasma from 10 mice were fractionated by gel
filtration chromatography on a Superose 6B column. 0.5-ml fractions were collected, and cholesterol was measured in mg/fraction. ApoE
(mg/fraction) was measured using an ELISA with antibodies specific for human (a huE (m)) (A) or mouse apoE (a muE (m)) (B). C and D, Western
blot analysis of FPLC fractions (C, 3/3 and D, 1/1) electrophoresed in 1% agarose gels and incubated with (a huE (p)) antiserum that cross-reacts
with mouse apoE.
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confirms that the IDL-like particles contain apoB (data not
shown). Interestingly, FPLC analysis of plasma from mice het-
erozygous for human apoE3 (3/1) showed a shift of the second
apoE3 peak to fractions 21–25, suggesting that the co-presence
of mouse ApoE reduces the size of remnant particles where
apoE3 accumulates (data not shown). An increase in mouse
ApoE, associated with larger particles, is also evident in the
heterozygote although approximately half of mouse ApoE was
still found associated with HDL.
Response to an Atherogenic Diet—The same 3/3 (n 5 12) and
1/1 (n 5 12) female mice used to measure lipid profiles on
normal chow were fed an atherogenic diet for 8 weeks to assess
any change in response to diet between the two groups. One
1/1 animal showed significant weight loss with a yellow col-
ored plasma during the diet study and was excluded. The 3/3
mice responded with a 5-fold increase in cholesterol (350 6 207
versus 67 6 18 mg/dl), whereas the cholesterol in control mice
increased about 1.5-fold (111 6 44 versus 73 6 20 mg/dl) (Table
I). Triglyceride levels in the 3/3 and 1/1 mice were reduced by
18 and 50%, respectively. HDL cholesterol levels were reduced
in both groups of mice to about the same extent (approximately
50%). Agarose gel electrophoresis of plasma from both types of
animals showed a decrease in a-migrating particles and an
increase in pre-b-migrating particles consistent with total lipid
measurements (data not shown). These results suggest that
there is a marked increase in remnant particles with concur-
rent reduction in HDL in response to the atherogenic diet in
both types of mice, but the extent of increase in the 3/3 mice is
much larger.
The elution profile in a Superose 6 gel filtration column of 3/3
plasma (Fig. 7A) showed that the majority of the (highly ele-
vated) cholesterol was in the VLDL-IDL fractions, whereas in
the 1/1 group (modestly increased) cholesterol was distributed
equally between the VLDL and HDL fractions (Fig. 7B). As
expected in the 1/1 mice, the distribution of apoE followed that
of cholesterol (Fig. 7B). The apoE distribution pattern in the 3/3
animals was highly unusual and was similar to that seen when
the same animals were fed a normal chow diet; again two
distinct classes of lipoproteins in the VLDL and IDL range
were associated with human APOE (Fig. 7A). There was a large
increase in plasma apoE in the 3/3 animals (10.80 6 5.60 versus
1.30 6 0.47 mg/dl) compared with no increase in the 1/1
animals (1.11 6 0.34 versus 1.13 6 0.23 mg/dl) between the two
diets (Table I).
The distributions of several other plasma apolipoproteins
were also different between the 3/3 and 1/1 mice fed the high
fat diet (Fig. 6B). A comparison of the apolipoprotein distribu-
tion among density fractions by SDS-PAGE in Fig. 6, A (normal
chow) and B (high fat), revealed a marked increase on the high
fat diet of apoE, AI, and AIV mainly in the 1.006–1.04 g/ml
fractions in the 1/1 mice. In contrast the 3/3 mice showed
increases in these proteins over the whole density range. Of
particular interest is the increase of apoAI in the 1.006 , d ,
1.04 fraction, and apoAIV in the 1.04 , d , 1.06 fraction in the
3/3 mice. The amount of apoB48 was increased in the 3/3 mice
compared with 1/1 mice, but their distribution was not
different.
Delayed Clearance of apoE-deficient b-VLDL in 3/3 Mice—
The marked increase of cholesterol-rich remnant particles seen
in the 3/3 animals in response to an atherogenic diet suggests
that human apoE3 is not as effective as its murine homologue
in the clearance of these particles in mice. To test this possi-
bility, we injected 14C-radiolabeled remnant particles (.72%
cholesterol ester) in the b-VLDL flotation range (prepared from
apoE-deficient mice) into mice fed normal chow and measured
the decay of label over a 4-h period. The decay of [14C]choles-
terol was rapid in the 1/1 mice and virtually complete in 15
min (Fig. 8). The fractional catabolic rate in 1/1 mice based on
a single compartment system was 0.12 6 0.002/min. Clearance
of the same lipoproteins in apoE (2/2) mice was considerably
slower, with a fractional catabolic rate of 0.005 6 0.0003/min.
The 3/3 mice had a rate (0.02 6 0.0003/min) 6-fold slower than
1/1 mice but more rapid than the apoE (2/2) mice. Note,
however, that within 2 h the amount of label remaining in the
3/3 mice had decreased to the same levels seen in the 1/1 mice.
Morphometric Evaluations of Aortic Lesions—After 3 months
on an atherogenic diet, 3/3 and 1/1 animals (all females) were
evaluated for atherosclerotic lesions. All measurements were
made from sections in the proximal aorta near the aortic valve
attachment sites. All six 3/3 animals developed substantial
atherosclerotic lesions with a logarithmic mean area of 6.4 3
104 mm2 (ranging from 2.4 3 104 to 16.8 3 104). In contrast four
out of five 1/1 animals developed fatty streak lesions that were
small, with a logarithmic mean area of 5.1 3 103 mm2 (ranging
from 2.9 3 103 to 9.2 3 103) (Fig. 9). One 1/1 animal had no
lesions. These observations clearly demonstrate that the 3/3
mice are much more susceptible to diet-induced atherosclerosis
than 1/1 mice.
DISCUSSION
We have successfully replaced the coding sequence of the
mouse apoE gene with the equivalent human APOE3 coding
region without altering any known endogenous regulatory se-
quences. Expression of the human apoE mRNA in the liver,
brain, and other tissues parallels that found normally in wild
type mice. Thus, the human APOE3 protein is functional and is
expressed at physiological levels in these modified mice,
thereby providing a model for studying the function of human
APOE3 in vivo.
To date, pronuclear injection of DNA has been used to gen-
erate transgenic animals expressing various forms of human
APOE to study its role in lipid metabolism (19–24, 47). There
FIG. 7. Distribution of cholesterol
and apoE in mice on a high fat (HF)
diet. A and B, plasma from 10 mice were
pooled from each group, and their lipopro-
teins were fractionated by gel filtration
chromatography on a Superose 6B col-
umn. 0.5-ml fractions were collected, and
cholesterol was measured in mg/fraction.
ApoE (mg/fraction) was measured using
an ELISA with antibodies specific for hu-
man (a huE (m)) (A) or mouse apoE (a
muE (m)) (B).
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are three severe limitations to this approach as follows: the
number of copies of the transgene can vary over wide ranges;
there are marked and uncontrolled differences in the expres-
sion of transgenes at different chromosomal locations; and the
presence of the endogenous mouse protein complicates the in-
terpretation of the results. Most importantly, rigorous compar-
isons between different isoforms are not possible because of the
variable expression inherent in conventional transgenic
animals.
Mice made by replacement of the endogenous mouse coding
region with the equivalent region of the human gene retain the
natural chromosomal context at the apoE locus. Thus, locus-
specific sequences and enhancers are not altered except for any
possible intragenic control sequences that differ between mice
and humans. Therefore, it was expected that tissue-specific
expression of the human replacement APOE3 gene would
closely parallel that of the endogenous mouse apoE gene. Our
mRNA studies show that this expectation was indeed fulfilled,
with the exception of intestinal apoE mRNA which was slightly
reduced in the 3/3 mice compared with the 1/1 mice. The
significance of this reduction in intestinal expression is not
clear, considering that intestinal apoE expression is very low
compared with other tissues and that chylomicrons originating
from the small intestine are known to contain very little apoE
(34, 35). Differences between the 3/3 and 1/1 mice conse-
quently are highly informative as far as function of the apoli-
poprotein itself are concerned. Thus, gene replacement demon-
strates the advantages over pronuclear injection in generating
transgenic animals.
The lipid profiles of the 3/3 and 1/1 mice are very similar
when the mice are maintained on a chow (low fat) diet, and the
fasting levels of total cholesterol, triglyceride, and HDL choles-
terol are essentially identical in the two animals. However,
when the same mice were fed a high fat diet, the 3/3 animals
responded with a 5-fold increase in total cholesterol compared
with a 1.5-fold increase in the 1/1 animals. Second, after 3
months on a high fat diet, the atherosclerotic plaques seen in
all the 3/3 animals were 13-fold larger than those observed in
the wild type controls. Third, there was a 6-fold slower clear-
ance rate of remnant lipoprotein particles in the 3/3 animals.
The accumulation of cholesterol and the delayed clearance of
remnant particles observed in the 3/3 animals are likely causes
of the increased susceptibility to lesion development.
The dramatic delay in clearance of remnant particles in the
3/3 mice was unexpected since previous studies using trans-
genic mice expressing human APOE have revealed normal or
enhanced clearance kinetics (22, 36). One possible explanation
for the observed delay in clearance is that the human APOE3
protein has a lower affinity to mouse LDLR and/or other recep-
tors than mouse ApoE because of species differences in their
structures. Mouse and human apoE differ in 30% of their
amino acid sequences with most of the differences being at the
amino and carboxyl termini (1). The receptor binding domain
(residues 136–160) is highly conserved between mouse and
human apoE since 21 of 25 residues are identical in this region
including seven residues designated as critical for receptor
binding (37, 38). The residues that differ have conservative
substitutions (e.g. methionine for leucine) that do not affect the
net charge or hydrophobicity of the protein and would not be
predicted to have any substantial effects on the protein confor-
mation (39). Thus, it must be ascribed to differences outside the
receptor binding domain if the affinity for the receptor differs
between the mouse and human apoE proteins. Species differ-
ences in the receptors that interact with apoE, such as the
LDLR, and low density lipoprotein receptor-related protein,
could also contribute to a lower affinity.
A dysfunctional interaction between human APOE3 and
mouse heparan sulfate proteoglycans (HSPG) may also contrib-
ute to the delay in clearance. It has been postulated that
HSPG’s are involved in the initial sequestration process that
enhances the uptake of apoE containing lipoproteins (40, 41).
The interaction of apoE with HSPG’s is thought to occur mainly
via electrostatic attraction (42). Human APOE3 has a cysteine
at position 112 where the mouse protein has an arginine at the
equivalent position (mouse apoE residue 104). This charge
difference could be significant, even though residue 112 is
outside the known heparin-binding domain.
The delayed clearance could also be due to protein-protein
interactions not involving receptors. Several proteins are
FIG. 9. Morphometric evaluation of atherosclerotic lesions in
mice fed an atherogenic diet. All mice were F2 females kept on an
atherogenic diet for 12 weeks before sacrifice. Measurements for each
animal were made from a single section in the proximal aorta near the
aortic valve attachment site. The logarithmic means of the lesion areas
from all six 3/3 mice and four of five 1/1 mice are indicated (p 5 0.006).
One 1/1 mouse had no lesions.
FIG. 8. The plasma clearance of ApoE(2/2) remnant particles
in controls and 3/3 mice. Three mice of each group (å, ApoE-deficient
mice (E2/2); l, 3/3; and l, 1/1) were injected with radiolabeled
apoE(2/2) remnant particles, and its clearance was measured for 4 h.
Each data point shows the mean 6 S.D. Abbreviations are: 3/3, ho-
mozygous human apoE3 mice; 1/1, wild type mice; E2/2, apoE-defi-
cient mice.
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known to interact with apoE and play a role in lipid metabo-
lism. For example, the interaction of apoE with hepatic and
lipoprotein lipases mediates/or enhances the catabolism of li-
poproteins (41). Lipoprotein particles containing human
APOE3 may be less efficient in this type of interaction than
mouse ApoE. This would have important consequences in the
remodeling and processing phase of lipoprotein catabolism.
Another consideration in the clearance experiment is that
the exogenously introduced remnant particles have to acquire
apoE prior to their removal by receptors. In 1/1 mice most of
the plasma apoE is associated with HDL particles that are
presumably the source of apoE used to clear the exogenously
added remnants. In the 3/3 animals, however, the majority of
plasma apoE3 is associated with large lipoproteins and may not
transfer as easily to exogenously added particles. In support of
this, we and others (27) have noted that the distributions of
apoE among mouse plasma lipoproteins analyzed by FPLC and
by ultracentrifugation do not always agree and that apoE as-
sociated with HDL are more readily lost by ultracentrifugation.
Although the capacity for apoE3 to exchange between different
classes of lipoproteins has not been documented, the decreased
ability of apoE3 to transfer from large lipoproteins may have
important implications.
The association of apoE3 with larger lipoproteins in mice
(Fig. 5, A and C) is different from observations made in humans
that demonstrate a preference of apoE3 for HDL (1, 43). It is
very unlikely that this difference is the result of a mutation
unexpectedly introduced into the APOE3 gene during its ma-
nipulation because in our work2 we observed that transgenic
apoE3 mice, in an endogenous apoE (2/2) background, had a
virtually identical apoE3 distribution pattern as seen in the 3/3
replacement mice. These mice were made by pronuclear injec-
tion of a human cosmid clone isolated from a different individ-
ual from the one we used to make our mice (24). Similar
findings were also reported by Taylor et al. (44) in transgenic
apoE3 mice (that also express mouse apoE) which showed that
the majority of human APOE3 resided in larger lipoprotein
particles using SDS-PAGE immunoblot analysis of fractions
separated by sequential density ultracentrifugation. In this
work the authors also found that mouse ApoE and human
APOE co-distributed among lipoproteins. This is different from
the results of our FPLC analysis of 3/1 heterozygote plasma
which shows that approximately half of the mouse ApoE and
only a minor fraction of human APOE3 was associated with
HDL (data not shown). It is not known whether the observed
differences between our work and Taylor et al. are the result of
different techniques used to fractionate the plasma lipopro-
teins or the result of different levels of human APOE and
mouse ApoE expression in the two types of mice. Further
characterization of these large apoE3-rich lipoprotein particles
is required to understand the observed delay in clearance in the
3/3 animals.
The reduced clearance rate of remnant particles in the 3/3
mice, whatever its cause eventually proves to be, is not suffi-
cient to cause any alteration in fasted plasma cholesterol levels
in these animals relative to their 1/1 littermates when the
animals are on a normal chow diet. The 3/3 mice are, however,
much more susceptible to diet-induced hyperlipidemia and ath-
erosclerosis than their 1/1 littermates. Possibly, on the high
fat diet a postprandial accumulation of b-VLDL’s occurs that
leads to the development of atherosclerosis, as suggested by
Zilversmit (45). In human APOE2 homozygous individuals
with type III hyperlipoproteinemia, there is an abnormal accu-
mulation of remnant particles that has been suggested to cause
accelerated coronary and peripheral vascular disease (46).
Even small changes in lipid metabolism that decrease the
clearance efficiency of lipoproteins are likely to have dramatic
effects on the development of atherosclerosis, and thus the 3/3
animals give us an opportunity to investigate what changes are
important.
In conclusion, we have demonstrated the use of targeted
gene replacement to generate mice expressing the most com-
mon human isoform, APOE3, at physiological levels. These
mice allow us to document the behavior of the human APOE3
isoform in vivo in mice without any co-expression of mouse
apoE. Future experiments comparing these mice with mice
expressing the human apoE2 and E4 isoforms created in an
identical manner should prove invaluable for studying diseases
related to the different human apoE isoforms.
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